Binaytara shared a post on LinkedIn:
‘These were patients with HER2 metastatic breast cancer and a median of six prior lines of treatment. We saw every patient responding, many with complete responses. The PFS in this trial was 20 months. It made me passionate about ADCs. I saw a revolution in this trial.’
Dr. Paolo Tarantino spoke about a clinical moment that shaped his career during his keynote at our Detroit 2026 Hematology & Oncology Practice Symposium.
The trial was DESTINY-Breast01. Patients with HER2-positive metastatic breast cancer, median of six prior lines of therapy. By line seven, the realistic conversation with most patients is about hospice, not response rates.
The results showed nearly every patient responding, many with complete responses. Median PFS was around 20 months, while comparator options were giving 2 to 3 months.
He said it was the trial that made him commit his career to ADC research.
It’s worth remembering that behind every phase 3 readout and FDA approval, there’s usually a moment like this – a dataset that convinces a clinician something has fundamentally changed. For Dr. Tarantino, DESTINY-Breast01 was that moment.
What was yours?
Read more about Dr Tarantino’s keynote.”
Other articles about Breast Cancer on OncoDaily.